Here are the S-3 shelf registrations from Maze Therapeutics, Inc. (MAZE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics, Inc. has filed an automatic shelf registration and established an at-the-market offering program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent. Shares will be sold from time to time at prevailing market prices, with Jefferies earning up to 3% in commissions.
The company plans to use any net proceeds for general corporate purposes, including research and development, working capital, capital spending, and potential acquisitions. Maze is a clinical-stage biopharmaceutical company focused on precision medicines for kidney and metabolic diseases, and it had 48,076,885 common shares outstanding as of September 30, 2025.